Abstract:The substantial growth of R&D expenditures over the last two decades, together with the continuous substitution of knowledge (intangible) capital for physical (tangible) capital in corporate production functions, has elevated the importance of R&D in the performance of business enterprises. At the same time, however, the evaluation of corporate R&D activities by investors is seriously hampered by antiquated accounting rules and insufficient disclosure by corporations. Despite the fact that the expected benefits of R&D stretch over extended periods of time, corporate investments in R&D are immediately written off in financial reports, leaving no trace of R&D capital on balance sheets and causing material distortions of reported profitability. After a brief review of statistics documenting the growth and economic importance of corporate R&D in the U.S., the article presents a comparison of R&D disclosure regulations among industrialized nations that shows U.S. rules to be the least flexible in allowing management discretion in how they measure and report R&D. Next the author surveys the large and growing body of empirical research on R&D, which provides strong testimony to the substantial contribution of R&D to corporate productivity and shareholder value. Moreover, despite widespread allegations of stock market “short termism” throughout the 1980s and early '90s, the research indicates “unequivocally” that capital markets consider investments in R&D as a significant value‐increasing activity. But if investors clearly demonstrate a willingness to take the long view of R&D, there is also evidence of undervaluation of some R&D‐intensive companies—particularly those with low profitability—as well as other potential costs to corporations and investors stemming from inadequate public information about R&D. To help correct the reporting biases and distortions of R&D, the author offers some suggestions for investors and analysts that follow R&D‐intensive companies. In particular, he proposes (1) adjustment of reported data to reflect the capitalization and amortization of (instead of expensing) corporate R&D and (2) the use of various quantitative measures for gauging research capabilities and output, including citations of the firm's patents and measures indicating the share of current revenues coming from products developed within recent years.

Research on the U.S.Federal Government's 2015 Fiscal Year R&D Budget,Focus Points and Enlightenments

Comparative study on structural transformation of R&D funds in PR China and USA

The United States Of America And Scientific Research

Analysis on the Relationship Between Original Innovations and Science Funds

International Comparison on Structural Transformation of R&D Funds Source and Chinese Choice of Transformation

NIH Portfolio Allocation, Lemmings, and the Silent Spring: A Time-Capsule Commentary & Its Update

A Comparison Between Chinese and American Governments in Financing the Scientific Research in Higher Educational Institutes

Funding Reform Research and Promoting Education Innovation

University Scientific Research Funds Management Method based on the Performance Budgeting Conception

Distribution Study on Government R&D Investment and Domestic Journal Publications

The Policy and Mechanism of American Federal Government Funding University Research

Should the Endless Frontier of Federal Science be Expanded?

Comparative Study on Output Performance of Major Public Funds in Terms of Chinese-language Publications

A Discussion on Governmental Research Grants.

The impact of US monetary policy on Chinese enterprises’ R&D investment

On Comparion Study of Optimization Distribution of Our R&D Funds

The Survey Index and Monitoring System of Health Research and Development (R&D) Funding Flows

The Role of Research Universities in the U.S. R&D Performance

Impact of the 2022 OSTP Memo: A Bibliometric Analysis of U.S. Federally Funded Publications, 2017-2021

ANALYZING GLOBAL EVOLUTION OF MATERIALS RESEARCH FUNDING AND ITS INFLUENCE ON INNOVATION LANDSCAPE: A CASE STUDY OF U.S. INVESTMENT STRATEGIES

R&D AND CAPITAL MARKETS